Non-alcoholic Fatty Liver Disease
-
Subject Areas on Research
-
A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism.
-
A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease.
-
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
-
Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.
-
American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases.
-
Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
-
Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum.
-
Biomarkers of NAFLD progression: a lipidomics approach to an epidemic.
-
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science.
-
Caspase-2 promotes obesity, the metabolic syndrome and nonalcoholic fatty liver disease.
-
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.
-
Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome.
-
Comparison of the frequency of coronary artery disease in alcohol-related versus non-alcohol-related endstage liver disease.
-
Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease.
-
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
-
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
-
Dietary and commercialized fructose: Sweet or sour?
-
Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling.
-
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
-
Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
-
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
-
From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world.
-
Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis.
-
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.
-
HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver disease.
-
Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease.
-
Hedgehog pathway and pediatric nonalcoholic fatty liver disease.
-
Hepatic FTO expression is increased in NASH and its silencing attenuates palmitic acid-induced lipotoxicity.
-
Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease.
-
Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis, prevention and treatment.
-
High circulatory leptin mediated NOX-2-peroxynitrite-miR21 axis activate mesangial cells and promotes renal inflammatory pathology in nonalcoholic fatty liver disease.
-
Hormone signaling and fatty liver in females: analysis of estrogen receptor α mutant mice.
-
Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
-
Implication of gut microbiota in nonalcoholic fatty liver disease.
-
Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms.
-
Iron deficiency in patients with nonalcoholic Fatty liver disease is associated with obesity, female gender, and low serum hepcidin.
-
Leptin is key to peroxynitrite-mediated oxidative stress and Kupffer cell activation in experimental non-alcoholic steatohepatitis.
-
Linearity, Bias, and Precision of Hepatic Proton Density Fat Fraction Measurements by Using MR Imaging: A Meta-Analysis.
-
Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children.
-
Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD.
-
Metabolomic analysis shows differential hepatic effects of T2 and T3 in rats after short-term feeding with high fat diet.
-
Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis.
-
Mitigation of autophagy ameliorates hepatocellular damage following ischemia-reperfusion injury in murine steatotic liver.
-
Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease.
-
NADPH Oxidase-Derived Peroxynitrite Drives Inflammation in Mice and Human Nonalcoholic Steatohepatitis via TLR4-Lipid Raft Recruitment.
-
NAFLD is associated with methylation shifts with relevance for the expression of genes involved in lipoprotein particle composition.
-
NAFLD, NASH and liver cancer.
-
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
-
NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease.
-
No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.
-
Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
-
Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation.
-
Nonalcoholic Steatohepatitis: Histopathology Basics Within a Broader Context.
-
Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease.
-
Novel Transcriptional Mechanisms for Regulating Metabolism by Thyroid Hormone.
-
Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease.
-
Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis.
-
Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis.
-
Paracrine Hedgehog signaling drives metabolic changes in hepatocellular carcinoma.
-
Pathogenesis of Nonalcoholic Steatohepatitis.
-
Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis.
-
Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease.
-
Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease.
-
Prolonged Delirium With Catatonia Following Orthotopic Liver Transplant Responsive to Memantine.
-
Purinergic receptor X7 is a key modulator of metabolic oxidative stress-mediated autophagy and inflammation in experimental nonalcoholic steatohepatitis.
-
Purinergic receptor X7 mediates leptin induced GLUT4 function in stellate cells in nonalcoholic steatohepatitis.
-
Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis.
-
Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis.
-
Regional anthropometric measures and hepatic fibrosis in patients with nonalcoholic Fatty liver disease.
-
Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.
-
Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease.
-
Repair-related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism.
-
Reply to Kim et al.
-
Reply: To PMID 24849310.
-
Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
-
Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
-
Role of Hedgehog Signaling Pathway in NASH.
-
S-Nitrosoglutathione Reductase Dysfunction Contributes to Obesity-Associated Hepatic Insulin Resistance via Regulating Autophagy.
-
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
-
Sparstolonin B attenuates early liver inflammation in experimental NASH by modulating TLR4 trafficking in lipid rafts via NADPH oxidase activation.
-
Sugar sweetened beverages and fatty liver disease: Rising concern and call to action.
-
Systematic integrative analysis of gene expression identifies HNF4A as the central gene in pathogenesis of non-alcoholic steatohepatitis.
-
Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers.
-
Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis.
-
The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
-
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
-
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.
-
The hedgehog pathway in nonalcoholic fatty liver disease.
-
The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.
-
Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity.
-
Upregulation of miR21 and repression of Grhl3 by leptin mediates sinusoidal endothelial injury in experimental nonalcoholic steatohepatitis.
-
Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis.